» Articles » PMID: 39062863

Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era

Abstract

Pancreatic cancer (PC) is an increasing cause of cancer-related death, with a dismal prognosis caused by its aggressive biology, the lack of clinical symptoms in the early phases of the disease, and the inefficacy of treatments. PC is characterized by a complex tumor microenvironment. The interaction of its cellular components plays a crucial role in tumor development and progression, contributing to the alteration of metabolism and cellular hyperproliferation, as well as to metastatic evolution and abnormal tumor-associated immunity. Furthermore, in response to intrinsic oncogenic alterations and the influence of the tumor microenvironment, cancer cells undergo a complex oncogene-directed metabolic reprogramming that includes changes in glucose utilization, lipid and amino acid metabolism, redox balance, and activation of recycling and scavenging pathways. The advent of omics sciences is revolutionizing the comprehension of the pathogenetic conundrum of pancreatic carcinogenesis. In particular, metabolomics and genomics has led to a more precise classification of PC into subtypes that show different biological behaviors and responses to treatments. The identification of molecular targets through the pharmacogenomic approach may help to personalize treatments. Novel specific biomarkers have been discovered using proteomics and metabolomics analyses. Radiomics allows for an earlier diagnosis through the computational analysis of imaging. However, the complexity, high expertise required, and costs of the omics approach are the main limitations for its use in clinical practice at present. In addition, the studies of extracellular vesicles (EVs), the use of organoids, the understanding of host-microbiota interactions, and more recently the advent of artificial intelligence are helping to make further steps towards precision and personalized medicine. This present review summarizes the main evidence for the application of omics sciences to the study of PC and the identification of future perspectives.

Citing Articles

The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer.

Vitale F, Zileri Dal Verme L, Paratore M, Negri M, Nista E, Ainora M Biomedicines. 2025; 12(12.

PMID: 39767746 PMC: 11673965. DOI: 10.3390/biomedicines12122840.


The close association of Muribaculum and PA (10:0/a-17:0) with the occurrence of pancreatic ductal adenocarcinoma and immunotherapy.

Wang E, Ren K, Wang X, Du S, Gao X, Niu W Front Immunol. 2024; 15:1505966.

PMID: 39676871 PMC: 11638228. DOI: 10.3389/fimmu.2024.1505966.

References
1.
Hosein A, Dougan S, Aguirre A, Maitra A . Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer. 2022; 3(3):272-286. DOI: 10.1038/s43018-022-00349-2. View

2.
Roviello G, Ramello M, Catalano M, DAngelo A, Conca R, Gasperoni S . Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Sci Rep. 2020; 10(1):19281. PMC: 7648798. DOI: 10.1038/s41598-020-76465-9. View

3.
Cheng S, Cheng Y, Jin Z, Xue H . Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019; 113:188-197. DOI: 10.1016/j.ejrad.2019.02.009. View

4.
Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

5.
Zhou X, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R . Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol. 2021; 9:743908. PMC: 8603393. DOI: 10.3389/fcell.2021.743908. View